Xencor/$XNCR
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Xencor
Xencor Inc a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab, and XmAb657. The group earns its revenue from collaboration agreements, product licensing agreements, and technology licensing agreements.
Ticker
$XNCR
Sector
Primary listing
Employees
250
Headquarters
Website
Xencor Metrics
BasicAdvanced
$996M
-
-$2.40
0.89
-
Price and volume
Market cap
$996M
Beta
0.89
52-week high
$26.42
52-week low
$6.92
Average daily volume
1.1M
Financial strength
Current ratio
5.341
Quick ratio
5.115
Long term debt to equity
25.677
Total debt to equity
34.328
Interest coverage (TTM)
-4.12%
Profitability
EBITDA (TTM)
-131.007
Gross margin (TTM)
-56.21%
Net profit margin (TTM)
-116.44%
Operating margin (TTM)
-96.92%
Effective tax rate (TTM)
-1.01%
Revenue per employee (TTM)
$590,000
Management effectiveness
Return on assets (TTM)
-10.44%
Return on equity (TTM)
-29.27%
Valuation
Price to revenue (TTM)
6.775
Price to book
1.6
Price to tangible book (TTM)
1.63
Price to free cash flow (TTM)
-7.255
Free cash flow yield (TTM)
-13.78%
Free cash flow per share (TTM)
-1.924
Growth
Revenue change (TTM)
-2.07%
Earnings per share change (TTM)
-23.12%
3-year revenue growth (CAGR)
-20.22%
10-year revenue growth (CAGR)
32.19%
3-year earnings per share growth (CAGR)
84.70%
10-year earnings per share growth (CAGR)
13.68%
What the Analysts think about Xencor
Analyst ratings (Buy, Hold, Sell) for Xencor stock.
Bulls say / Bears say
Second quarter 2025 revenue increased 82% year-over-year to $43.6 million, boosted by milestone payments from Incyte and royalties from Alexion, well above previous levels.
Xencor had $663.8 million in cash, cash equivalents, and marketable securities as of June 30, 2025, ensuring funding through 2028 for ongoing R&D.
Interim Phase 1 data for XmAb942 showed a human half-life exceeding 71 days and a favorable safety profile, supporting a once-every-12-weeks dosing schedule and allowing the global Phase 2b XENITH-UC study to start in the second half of 2025.
Xencor reported a net loss of $30.8 million, or $(0.41) per share, for Q2 2025, highlighting ongoing unprofitability despite higher revenues.
Research and development expenses stayed high at $61.7 million in Q2 2025, virtually unchanged from a year ago, indicating substantial cash outflows on clinical projects.
More than 95% of revenue in Q2 2025 came from milestone and royalty payments instead of product sales, which may cause instability in future revenue growth.
Data summarised monthly by Lightyear AI. Last updated on 6 Oct 2025.
Xencor Financial Performance
Revenues and expenses
Xencor Earnings Performance
Company profitability
Xencor News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Xencor stock?
Xencor (XNCR) has a market cap of $996M as of October 14, 2025.
What is the P/E ratio for Xencor stock?
The price to earnings (P/E) ratio for Xencor (XNCR) stock is 0 as of October 14, 2025.
Does Xencor stock pay dividends?
No, Xencor (XNCR) stock does not pay dividends to its shareholders as of October 14, 2025.
When is the next Xencor dividend payment date?
Xencor (XNCR) stock does not pay dividends to its shareholders.
What is the beta indicator for Xencor?
Xencor (XNCR) has a beta rating of 0.89. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.